Workflow
Corporate misrepresentation
icon
Search documents
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Varonis Systems, Inc. Common Stock and Sets a Lead Plaintiff Deadline of March 9, 2026
Globenewswire· 2026-01-07 20:37
Core Viewpoint - A class action lawsuit has been filed against Varonis Systems, Inc. due to allegations of misleading statements regarding its financial performance and customer retention capabilities, leading to significant stock price decline [1][3][4]. Company Performance - Varonis reported a significant miss in Annual Recurring Revenue (ARR) for Q3 2025 and lowered its full-year guidance, attributing this to weaker-than-expected renewals and conversions in its subscription business [4]. - The company announced the end of life for its self-hosted solution and a 5% reduction in headcount as part of its restructuring efforts [4]. Stock Market Reaction - Following the announcement of disappointing financial results, Varonis' stock price plummeted from $63.00 per share on October 28, 2025, to $32.34 per share on October 29, 2025, marking a decline of approximately 48.67% in just one day [5]. Legal Proceedings - The lawsuit, Artem Molchanov v. Varonis Systems, Inc., has been initiated in the U.S. District Court for the Southern District of New York, targeting investors who purchased Varonis stock between February 4, 2025, and October 28, 2025 [1][3]. - Investors are encouraged to step forward before the March 9, 2026 deadline to seek compensation for losses incurred due to alleged corporate misrepresentations [6].
LMT 10-DAY DEADLINE ALERT: Did Lockheed Martin (LMT) Mislead Investors on Financial Health? -- Hagens Berman
Prnewswire· 2025-09-16 22:04
Core Viewpoint - A securities class action lawsuit has been filed against Lockheed Martin Corporation, alleging that the company misled investors regarding its financial health and internal controls from January 23, 2024, to July 21, 2025 [1][2]. Group 1: Allegations and Misrepresentations - The lawsuit claims Lockheed Martin overstated its operational capabilities, particularly in the Aeronautics and Rotary and Mission Systems (RMS) segments, and lacked effective internal controls to assess program risks [2]. - Investors were not informed of the potential for significant losses due to these inadequate internal controls, which the lawsuit suggests were systemic issues rather than isolated incidents [5]. Group 2: Financial Disclosures and Impact - A series of negative disclosures led to substantial stock price drops, with shares falling nearly 11% following the final disclosure [3]. - Specific financial losses reported include $1.8 billion in pre-tax losses in the Aeronautics segment on January 28, 2025, and an additional $950 million and $570 million in pre-tax losses for the Aeronautics and RMS segments, respectively, disclosed on July 22, 2025 [6]. Group 3: Legal and Investigative Actions - Hagens Berman is investigating the claims on behalf of investors who suffered losses, focusing on whether the company's management was aware of the inadequacies in internal controls and the risks involved [4][5]. - The firm encourages investors with substantial losses to come forward and assist in the investigation [2].
CNC Investor Update: Lawsuit Filed Against Centene (CNC) Over Enrollment – Hagens Berman
GlobeNewswire News Room· 2025-08-22 15:50
Core Viewpoint - A securities class-action lawsuit has been filed against Centene Corporation, alleging that the company misrepresented its financial health and market conditions to investors [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, targets investors who purchased Centene securities between December 12, 2024, and June 30, 2025 [1]. - The complaint claims that Centene's leadership provided a misleadingly optimistic view of projected revenue growth, strong enrollment, and low morbidity levels, which contradicted internal data [2]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 financial guidance after an independent actuarial review indicated that market growth was "lower than expected" and morbidity levels were "materially inconsistent" with prior assumptions, leading to a stock price drop of over 40% [3]. - Following the lawsuit, Centene reported a Q2 diluted loss per share of -$0.51, attributed to reduced revenue estimates [4]. Group 3: Investigation and Whistleblower Information - Hagens Berman, a national plaintiffs' rights law firm, is investigating claims on behalf of investors who suffered losses, focusing on whether Centene misrepresented its marketplace business health [5]. - The firm encourages whistleblowers with non-public information about Centene to come forward, offering potential rewards of up to 30% of any successful SEC recovery [5].